Professor and Chairman
Radiation Oncology
Dr. Eric M. Horwitz, MD
|
|
Give Review
Eric Horwitz works in the field of Radiation Oncology. He went to medical school at Albany Medical College. He has 12 awards "Volunteer Service Award", "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "Best Doctors in America", "Recipient of the Best Abstract Award", "Top Docs", "Recipient of Resident/Fellow Research Award", "Recipient of the 4th Annual Delmar H. Mahrt, M.D. Resident Research Competition Award", "Recipient of Medical Student Summer Research Fellowship", "Phi Alpha Theta (National History Honor Society)" and "Distinguished Service Award". Doctor Eric M. Horwitz, MD is a published doctor and has 93 publications published. The lastest was: 'Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.' He accepts all Medicare patients.
Publications
- Advanced small cell carcinoma of the Bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.
- Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.
- What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey.
- Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer.
- Evaluating toxicity from definitive radiation therapy for prostate Cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with mode...
- The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate Cancer in the National Cancer Data Base.
- Prostate Cancer, version 1.2014.
- Randomized trial of hypofractionated external-beam radiotherapy for prostate Cancer.
- Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
- Reduction of Prostate intrafractional motion from shortening the treatment time.
- A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints.
- In reply to cheung.
- The impact of dose-escalated radiotherapy plus androgen deprivation for prostate Cancer using 2 linked nomograms.
- Aspirin and statin nonuse associated with early biochemical failure after Prostate radiation therapy.
- Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate Cancer treated with external beam radiother...
- Hypoxic prostate/muscle po(2) ratio predicts for outcome in patients with localized prostate Cancer: long-term results.
- Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate Cancer.
- Radiotherapy Doses of 80 Gy and Higher are Associated with Lower Mortality in Men with Gleason Score 8 to 10 Prostate Cancer.
- Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate Cancer.
- Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate Cancer.
- Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-a...
- PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.
- Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.
- An intraoperative real-time sleeved seed technique for permanent Prostate brachytherapy.
- NCCN clinical practice guidelines in oncology: prostate Cancer.
- Gains from real-time tracking of Prostate motion during external beam radiation therapy.
- Why external beam radiotherapy is treatment of choice for most men with early-stage nonmetastatic prostate Cancer.
- Does treatment duration affect outcome after radiotherapy for prostate Cancer?
- Residual prostate Cancer after radiotherapy: a study of radical cystoprostatectomy specimens.
- A comparison of acute and chronic toxicity for men with low-risk prostate Cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
- Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced Prostate ...
- Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate Cancer?
- How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
- Interval to biochemical failure highly prognostic for distant metastasis and prostate Cancer-specific mortality after radiotherapy.
- The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate Cancer.
- Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.
- Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the ...
- What dose of external-beam radiation is high enough for prostate Cancer?
- Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate Cancer after radiotherapy.
- Role of radiotherapy in ductal (endometrioid) carcinoma of the Prostate.
- Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate Cancer cells: implications for chemoprevention.
- The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate Cancer.
- Radiation dose and late failures in prostate Cancer.
- Multi-institutional analysis of long-term outcome for stages T1-T2 prostate Cancer treated with permanent seed implantation.
- Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate Cancer: a prospective evaluation.
- Prostate-specific antigen nadir within 12 months of prostate Cancer radiotherapy predicts metastasis and death.
- Nadir Prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
- Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate Cancer.
- Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate Cancer patients treated with external beam radiation therapy a...
- A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate Cancer.
- Comparison of biochemical failure definitions for permanent Prostate brachytherapy.
- Increasing external beam dose for T1-T2 prostate Cancer: effect on risk groups.
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate Cancer: a multi-institutional analysis.
- Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, o...
- Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate Cancer on a randomized hypofractionation dose escalation trial.
- Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate Cancer.
- Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with Prostate carcinoma?
- Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate Cancer patients treated with three-dimensional conformal radiation therapy.
- Toxicity and outcome analysis of patients with recurrent head and neck Cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and pa...
- Biochemical failure and the temporal kinetics of Prostate-specific antigen after radiation therapy with androgen deprivation.
- What pretreatment Prostate-specific antigen level warrants long-term androgen deprivation?
- Definitions of biochemical failure that best predict clinical failure in patients with prostate Cancer treated with external beam radiation alone: a multi-institutiona...
- Role of Prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
- In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
- Androgen suppression plus radiation therapy for prostate Cancer.
- The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
- A comparison of the single and double factor high-risk models for risk assignment of prostate Cancer treated with 3D conformal radiotherapy.
- Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate Cancer: results from the search database.
- Prostate Cancer radiotherapy dose response: an update of the fox chase experience.
- Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate Cancer treatment.
- The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate Cancer.
- Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate Cancer.
- Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate Cancer patients treated by external beam radiotherapy between 1986...
- Long-term multi-institutional analysis of stage T1-T2 prostate Cancer treated with radiotherapy in the PSA era.
- Brachytherapy for prostate Cancer: follow-up and management of treatment failures.
- Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate Cancer?
- Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate Cancer: implications for the alpha/beta ratio.
- Biochemical failure as a determinant of distant metastasis and death in prostate Cancer treated with radiotherapy.
- Positive Prostate biopsy laterality and implications for staging.
- The Gleason score shift: score four and seven years ago.
- Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prosta...
- Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate Cancer treatment.
- Free prostate-specific antigen improves prostate Cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
- Treatment of prostate Cancer with regional lymph node (N1) metastasis.
- Validation of a treatment policy for patients with Prostate specific antigen failure after three-dimensional conformal Prostate radiation therapy.
- Late morbidity profiles in prostate Cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement.
- Dose response in prostate Cancer with 8-12 years' follow-up.
- Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate Cancer: preliminary findings.
- In regard to Sherertz et al., IJROBP 2001; 51:1241-1245.
- Biochemical failure rates in prostate Cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy.
- Advantages of using noncoplanar vs. axial beam arrangements when treating prostate Cancer with intensity-modulated radiation therapy and the step-and-shoot delivery me...
- Relationship between Prostate volume, Prostate-specific antigen nadir, and biochemical control.
Schools
Albany Medical College
Wm Beaumont Hospital
Procedures Preformed
- Brachytherapy
- Image-Guided Radiation Therapy (IGRT)
- Intensity-Modulated Radiation Therapy (IMRT)
Conditions Treated
- Bladder Cancer
- Prostate Cancer
- Testicular Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Aetna
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Assurant Health
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Golden Rule
- GEHA
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- Volunteer Service Award
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- Best Doctors in America®
- Recipient of the Best Abstract Award
- Top Docs
- Recipient of Resident/Fellow Research Award
- Recipient of the 4th Annual Delmar H. Mahrt, M.D. Resident Research Competition Award
- Recipient of Medical Student Summer Research Fellowship
- Phi Alpha Theta (National History Honor Society)
- Distinguished Service Award
Education
-
William Beaumont Hospital -
Albany Medical College
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital
Drug Facts
| NPI NUMBER | 1952322679 | |
| NPPES Provider LastName | HORWITZ | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 191112434 | |
| NPPES Provider State | PA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 197.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952322679 |
| Last Name Of The Provider | HORWITZ |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. Ildiko Csiki, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Talha A. Shaikh, MD |
|
|
Dr. Steven J. Feigenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas M. Churilla, MD |
|
|
Dr. Xinglei Shen, MD |
|
Dr. Bernard F. Schneider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan D. Jones, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine E. Hill-Kayser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith A. Cengel, MD
This Doctor is OpenDoctor Recommended.
|